inflammatori
respons
associ
clinic
sever
copd
exacerb
greatli
variabl
determin
factor
poorli
understood
examin
hypothesi
bacteria
virus
may
modul
heterogen
interact
bacteri
viral
infect
may
affect
chang
airway
bacteri
load
clinic
featur
inflammatori
respons
exacerb
patient
copd
design
prospect
cohort
studi
set
outpati
depart
london
chest
hospit
london
uk
patient
thirtynin
patient
copd
measur
prospect
studi
copd
exacerb
obtain
clinic
data
pair
sputum
serum
sampl
baselin
exacerb
qualit
quantit
microbiolog
polymeras
chain
reaction
detect
rhinoviru
estim
cytokin
level
enzymelink
immunosorb
assay
perform
result
total
exacerb
associ
bacteri
pathogen
commonli
haemophilu
influenza
rhinoviru
identifi
exacerb
rise
bacteri
load
exacerb
correl
rise
sputum
interleukin
il
r
p
fall
fev
r
p
exacerb
rhinoviru
h
influenza
higher
bacteri
load
cfuml
vs
cfuml
p
serum
pgml
vs
pgml
p
exacerb
without
pathogen
exacerb
cold
symptom
marker
put
viral
infect
bacteri
pathogen
fev
fall
greater
vs
p
symptom
count
higher
p
bacteri
pathogen
alon
abbrevi
ci
confid
interv
hrv
human
rhinoviru
il
interleukin
iqr
interquartil
rang
pcr
polymeras
chain
reaction
ppm
potenti
pathogen
microorgan
e
xacerb
copd
character
increas
airway
system
inflamm
howev
mark
variabl
natur
inflammatori
respons
exacerb
thu
symptom
clinic
sever
time
cours
event
individu
factor
respiratori
virus
particular
bacteri
pathogen
associ
index
sever
exacerb
howev
interact
individu
pathogen
mechan
underli
heterogen
exacerb
poorli
understood
bacteri
pathogen
commonli
identifi
lower
airway
copd
patient
stabl
state
airway
inflamm
directli
relat
number
bacteria
lower
airway
stabl
copd
greater
airway
bacteri
load
stimulu
faster
diseas
progress
known
airway
bacteri
load
rise
exacerb
known
extent
rise
modul
chang
airway
inflamm
exacerb
sever
factor
determin
chang
bacteri
load
respiratori
virus
implic
import
infect
trigger
exacerb
human
rhinoviru
hrv
commonli
identifi
viral
pathogen
virusassoci
exacerb
longer
thu
sever
nonvir
exacerb
whether
due
direct
effect
viral
infect
airway
mechan
involv
chang
lower
airway
bacteria
known
examin
hypothesi
heterogen
inflammatori
symptomat
physiolog
respons
copd
exacerb
modul
airway
bacteri
viral
infect
combin
pathogen
would
result
greater
airway
system
inflamm
henc
clinic
physiolog
index
exacerb
sever
patient
copd
recruit
outpati
depart
london
chest
hospit
east
london
copd
cohort
inclus
criteria
studi
previous
publish
includ
postbronchodil
fev
predict
age
height
agonist
revers
baselin
andor
ml
fev
fvc
ratio
patient
assess
clinic
chest
radiographi
recruit
ensur
absenc
signific
respiratori
diseas
patient
observ
studi
april
juli
ethic
approv
studi
obtain
east
london
citi
health
author
research
ethic
committe
patient
gave
written
inform
consent
patient
cohort
subject
previou
articl
variou
aspect
copd
exacerb
recruit
patient
taught
record
diari
card
morn
postbronchodil
peak
expiratori
flow
miniwright
clement
clark
intern
harlow
uk
patient
record
chang
symptom
use
letterannot
system
well
stabl
patient
instruct
record
symptom
letter
diari
howev
perceiv
increas
normal
stabl
condit
symptom
major
minor
see
note
correspond
symptom
letter
diari
card
therefor
patient
record
symptom
letter
symptom
perceiv
wors
eg
dyspnea
new
onset
eg
sore
throat
latter
usual
present
patient
review
recruit
diari
card
everi
month
studi
clinic
monitor
complianc
data
collect
record
chang
medic
baselin
lung
function
review
diari
card
util
ensur
stabl
sampl
perform
subject
clear
exacerb
symptom
complet
exacerb
treatment
least
week
patient
encourag
report
symptom
chang
studi
team
assess
within
h
studi
clinic
respiratori
physician
prior
initi
therapi
exacerb
diagnosi
exacerb
base
symptomat
criteria
previous
valid
group
exacerb
defin
presenc
least
consecut
day
increas
two
major
symptom
dyspnea
sputum
purul
sputum
amount
increas
one
major
one
minor
symptom
wheez
sore
throat
cough
symptom
common
cold
exacerb
symptom
binari
code
present
absent
sum
exacerb
onset
term
symptom
count
valid
marker
clinic
sever
lung
function
measur
sputum
blood
sampl
perform
patient
prior
initi
exacerb
treatment
lung
function
measur
roll
seal
spiromet
sensormed
yorba
linda
ca
lung
function
measur
obtain
h
patient
usual
bronchodil
medic
least
three
spirometri
read
obtain
visit
best
perform
record
sputum
sampl
subject
met
criteria
stabl
state
review
also
present
exacerb
immedi
follow
lung
function
measur
patient
ask
spontan
expector
sputum
steril
contain
patient
unabl
produc
sampl
sputum
spontan
underw
sputum
induct
sampl
obtain
sputum
plug
separ
saliva
use
steril
forcep
one
third
sputum
taken
analyz
quantit
bacteri
cultur
remaind
homogen
centrifug
aliquot
supernat
store
later
cytokin
analysi
sputum
sampl
contain
squamou
epitheli
cell
per
lowpow
field
leukocyt
per
highpow
field
accept
analysi
aliquot
phosphatebuff
salin
solutionprocess
sputum
frozen
subsequ
rna
extract
polymeras
chain
reaction
pcr
remaind
analyz
inflammatori
cytokin
sputum
interleukin
il
level
measur
use
enzymelink
immunosorb
assay
r
system
abingdon
uk
contemporan
blood
sampl
obtain
centrifug
serum
decant
store
subsequ
analysi
level
use
enzymelink
immunosorb
assay
r
system
sampl
process
homogen
tenfold
serial
dilut
homogen
sampl
made
brain
heart
infus
broth
aliquot
plate
onto
surfac
rang
differ
media
includ
blood
agar
chocol
agar
macconkey
agar
cystein
lactos
electrolytedefici
agar
incub
h
atmospher
air
carbon
dioxid
incub
bacteri
coloni
count
subcultur
identif
standard
method
haemophilu
influenza
haemophilu
parainfluenza
identifi
differenti
growth
pattern
pepton
agar
disc
contain
nicotinamid
adenosin
dinucleotid
haemin
place
oxoid
unipath
basingstok
uk
number
coloni
form
unit
per
millilit
sputum
calcul
number
coloni
obtain
dilut
sputum
bacteriolog
data
express
total
bacteri
count
log
base
u
potenti
pathogen
microorgan
ppm
bacteria
known
common
pathogen
respiratori
tract
subject
copd
streptococcu
pneumonia
h
influenza
h
moraxella
catarrhali
staphylococcu
aureu
pseudomona
aeruginosa
gramneg
enter
bacteria
rna
extract
sputum
perform
use
standard
extract
kit
qiagen
southampton
uk
revers
transcript
perform
use
random
hexam
picornaviru
pcr
perform
previous
describ
pcr
techniqu
valid
detect
rhinoviru
sampl
use
confirmatori
nucleic
acid
sequenc
normal
distribut
data
report
mean
sd
skew
data
present
median
interquartil
rang
iqr
correl
assess
use
pearson
spearman
correl
coeffici
two
tail
appropri
continu
variabl
normal
distribut
compar
test
wherea
nonnorm
distribut
compar
mannwhitney
u
wilcoxon
signedrank
test
chang
paramet
stabl
state
exacerb
assess
use
pair
analysi
stabl
sampl
data
taken
preced
exacerb
studi
p
valu
regard
signific
analysi
chang
paramet
stabl
state
exacerb
prior
stabl
sampl
point
closest
subject
correspond
exacerb
use
creat
data
set
pair
baselin
exacerb
sampl
exacerb
analysi
group
data
initi
adjust
repeat
measur
select
first
exacerb
sampl
per
patient
n
assess
chang
measur
index
baselin
exacerb
observ
chang
compar
larger
data
set
exacerb
patient
therefor
use
compar
individu
exacerb
characterist
etiolog
previou
studi
multivari
analysi
perform
use
multipl
linear
regress
analysi
data
analysi
perform
use
statist
softwar
spss
version
spss
chicago
il
tabl
show
baselin
characterist
patient
east
london
copd
cohort
sampl
studi
fiftysix
pair
stabl
exacerb
sampl
obtain
patient
analysi
patient
receiv
longterm
oxygen
therapi
patient
receiv
longterm
inhal
corticosteroid
median
gd
iqr
gd
beclomethason
equival
patient
receiv
longterm
oral
corticosteroid
patient
receiv
regular
inhal
bronchodil
remaind
patient
exacerb
sampl
period
n
report
exacerb
studi
team
receiv
antibiot
treatment
sampl
unabl
provid
adequ
sputum
sampl
n
sampl
patient
differ
significantli
term
baselin
characterist
sampl
tabl
tabl
show
stabl
exacerb
fev
airway
bacteri
load
sputum
blood
level
sampl
exacerb
perpati
basi
n
analys
mean
fev
fell
exacerb
mean
airway
bacteri
load
rose
significantli
exacerb
associ
increas
airway
inflamm
term
sputum
rise
level
sputum
serum
reach
statist
signific
airway
bacteri
load
rose
sampl
n
log
cfuml
stabl
state
log
cfuml
exacerb
also
rose
significantli
data
adjust
repeat
measur
chang
airway
bacteri
load
n
relat
exacerb
sever
term
chang
lung
function
airway
inflamm
rise
airway
bacteri
load
baselin
exacerb
relat
percentag
fall
fev
r
p
magnitud
rise
airway
exacerb
relat
rise
airway
bacteri
load
p
chang
airway
serum
observ
stabl
state
exacerb
relat
chang
bacteri
load
p
p
respect
howev
rise
system
inflamm
relat
airway
inflamm
chang
sputum
correl
chang
serum
p
n
chang
airway
system
marker
inflamm
exacerb
modul
exist
diseas
sever
observ
chang
sputum
exacerb
per
patient
invers
relat
baselin
fev
percentag
predict
p
chang
sputum
p
chang
serum
p
thu
patient
sever
copd
exhibit
greater
rise
inflamm
exacerb
compar
mild
diseas
h
influenza
h
influenzaerel
exacerb
associ
higher
airway
bacteri
load
n
log
cfuml
compar
case
isol
log
cfuml
p
trend
toward
sever
drop
fev
express
percentag
baselin
sd
hrv
cold
hrv
pcr
find
posit
exacerb
cold
symptom
measur
put
viral
infect
present
case
presenc
cold
symptom
hrvposit
pcr
sputum
relat
continu
adjust
p
exacerb
associ
cold
associ
greater
percentag
fall
fev
sd
without
cold
sd
p
observ
fev
fall
associ
cold
exacerb
mark
presenc
lower
airway
bacteri
pathogen
sd
cold
bacteri
pathogen
compar
sd
cold
alon
p
sd
bacteri
pathogen
alon
p
fig
specif
effect
interact
cold
bacteri
pathogen
assess
multivari
regress
analysi
percentag
fev
fall
exacerb
depend
variabl
effect
interact
addit
independ
effect
individu
factor
confid
interv
ci
p
similarli
exacerb
symptom
sever
higher
symptom
count
exacerb
onset
exacerb
associ
ppm
presenc
cold
symptom
exacerb
associ
h
influenza
hrv
exhibit
greater
bacteri
load
log
cfuml
vs
log
cfuml
p
serum
pgml
iqr
pgml
vs
pgml
iqr
pgml
p
without
pathogen
exacerb
airway
bacteri
load
associ
h
influenza
hrv
compar
ppm
illustr
figur
result
studi
show
first
time
synergist
effect
viral
bacteri
infect
modul
sever
symptom
lung
function
chang
inflamm
exacerb
copd
find
demonstr
chang
lower
airway
bacteri
load
associ
variabl
inflamm
lung
function
seen
exacerb
patient
moderatetosever
copd
effect
pronounc
proven
rhinovir
put
viral
infect
data
also
suggest
pathogen
associ
sever
exacerb
h
influenza
may
act
least
part
via
greater
stimulu
inflamm
associ
higher
airway
bacteri
load
patient
sever
diseas
studi
demonstr
greater
rise
airway
system
inflamm
milder
diseas
suggest
heterogen
natur
exacerb
sever
depend
natur
infect
trigger
also
baselin
sever
diseas
studi
perform
use
wellvalid
techniqu
daili
diari
card
symptom
record
analysi
confirm
diagnosi
exacerb
also
stabl
state
studi
design
allow
us
sampl
patient
clinic
state
describ
crosssect
analys
exacerb
also
chang
baselin
furthermor
chang
exacerb
paramet
modul
correspond
infecti
agent
found
sever
fall
lung
function
rise
inflamm
seen
exacerb
relat
extent
rise
airway
bacteri
load
relationship
airway
inflamm
airway
bacteri
load
previous
describ
stabl
state
higher
load
associ
greater
fall
fev
studi
number
previou
studi
identifi
bacteri
pathogen
commonli
found
lower
airway
exacerb
higher
load
stabl
state
howev
effect
rise
number
bacteria
natur
exacerb
investig
find
suggest
chang
bacteri
load
may
play
role
heighten
level
airway
inflamm
characterist
exacerb
howev
evid
associ
chang
bacteri
load
index
exacerb
sever
prove
causal
possibl
chang
airway
bacteri
load
may
simpli
secondari
phenomenon
caus
inflamm
inde
find
studi
show
key
chang
symptom
lung
function
exacerb
observ
synergist
effect
viral
bacteri
infect
found
vitro
intervent
studi
requir
differenti
exact
contribut
particular
pathogen
pathogen
inflammatori
pathophysiolog
chang
exacerb
h
influenza
found
studi
previou
studi
import
bacteri
pathogen
identifi
term
preval
stabl
state
exacerb
determin
airway
bacteri
load
h
influenza
unlik
number
bacteri
pathogen
may
colon
airway
respiratori
epithelium
h
influenza
colon
shown
greater
stimulu
airway
inflamm
commonli
isol
pathogen
agreement
find
studi
demonstr
h
influenza
present
greater
number
ppm
identifi
presenc
exacerb
associ
sever
drop
fev
role
less
preval
bacteri
pathogen
exacerb
particular
interact
respiratori
virus
requir
studi
stimulu
newli
acquir
h
influenza
exacerb
provid
greater
deleteri
effect
fev
h
influenzaeassoci
exacerb
patient
alreadi
colon
pathogen
find
compliment
previou
work
role
strain
chang
particular
bacteri
speci
play
etiolog
exacerb
identifi
role
new
antigen
stimulu
airway
immun
system
play
pathogenesi
exacerb
feasibl
acquisit
new
bacteri
strain
type
may
provid
direct
antigen
stimulu
also
overcom
establish
hostpathogen
balanc
allow
bacteri
prolifer
thu
inflammatori
stimulu
due
greater
bacteri
number
date
studi
determin
possibl
interact
viral
infect
bacteri
strain
chang
perform
may
provid
inform
complex
mechan
result
trigger
exacerb
respiratori
viral
infect
import
trigger
airway
immun
system
cohort
influenzavaccin
patient
previous
demonstr
hrv
commonli
isol
viru
exacerb
rhinoviru
isol
lower
airway
sampl
associ
greater
level
inflamm
nonvir
infect
similarli
shown
cold
marker
put
viral
infect
associ
sever
exacerb
studi
system
inflamm
serum
exacerb
symptom
lung
function
chang
sever
evid
bacteri
viral
infect
present
possibl
effect
may
due
separ
addit
inflammatori
stimuli
two
separ
pathogen
airway
howev
explan
support
multivari
analysi
indic
synergist
effect
lung
function
addit
individu
effect
pathogen
type
furthermor
exacerb
associ
higher
bacteri
load
pathogen
present
may
suggest
synergist
interact
effect
viral
infect
allow
greater
prolifer
airway
bacteria
viral
infect
therefor
may
impact
exacerb
sever
indirectli
increas
bacteri
load
addit
direct
effect
viral
infect
eg
heighten
inflamm
airway
hyperrespons
independ
pathogen
hrv
common
viru
identifi
exacerb
henc
target
investig
studi
number
respiratori
virus
identifi
airway
event
exampl
coronaviru
role
viral
pathogen
atyp
bacteria
exacerb
remain
uncertain
requir
investig
mechan
viral
infect
may
facilit
airway
bacteri
growth
like
complex
howev
disrupt
innat
defens
respiratori
epithelium
lower
airway
colon
bacteria
may
unsettl
fine
balanc
host
immun
bacteri
number
rhinovir
infect
known
increas
mucou
product
neutrophil
inflamm
direct
evid
rhinovir
infect
increas
suscept
bacteri
adher
airway
epitheli
cell
key
process
bacteri
infect
avail
vitro
studi
inde
key
cell
surfac
bind
site
hrv
infect
intracellular
adhes
upregul
hrv
infect
bacteri
colon
increas
may
play
key
role
neutrophil
elastasemedi
inflamm
henc
number
mechan
viral
infect
may
alter
immun
environ
may
allow
either
prolifer
colon
airway
bacteria
new
pathogen
infect
lower
airway
studi
perform
patient
moderatetosever
copd
role
bacteri
infect
therefor
potenti
bacterialvir
interact
like
vari
diseas
sever
therefor
preval
bacteri
colon
inde
shown
degre
airway
system
inflammatori
respons
exacerb
relat
baselin
diseas
sever
suggest
sever
inflammatori
respons
may
progress
diseas
sever
agreement
find
longitudin
analysi
exacerb
studi
requir
determin
find
extrapol
copd
patient
milder
diseas
inde
observ
heterogen
exacerb
like
modul
rel
frequenc
particular
pathogen
henc
may
show
season
may
explain
differ
associ
cytokin
respons
found
studi
compar
sampl
size
similarli
differ
techniqu
sampl
spontan
induc
sputum
may
affect
observ
result
howev
previous
demonstr
two
techniqu
compar
assess
lower
airway
inflamm
therapi
must
also
consid
import
consid
factor
modul
inflammatori
respons
patient
sampl
studi
receiv
inhal
steroid
baselin
sampl
exacerb
possibl
inflammatori
respons
observ
exacerb
modifi
effect
treatment
statist
analysi
effect
feasibl
due
ubiqu
inhal
steroid
use
patient
group
therefor
modul
influenc
natur
exacerb
numer
probabl
individu
factor
play
contribut
rather
definit
role
determin
natur
sever
particular
exacerb
furthermor
potenti
interact
factor
modul
characterist
event
find
studi
suggest
chang
airway
bacteri
load
natur
individu
infect
pathogen
interact
multipl
pathogen
airway
modul
exacerb
sever
studi
requir
improv
understand
pathogenhost
interact
exacerb
inde
also
stabl
state
manipul
complex
relationship
appropri
antiinfect
antiinflammatori
therapi
may
benefit
copd
patient
reduc
exacerb
sever
slow
progress
highli
preval
diseas
